Regent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025

Reuters

2025/07/22

<a href="https://laohu8.com/S/RPGLF">Regent Pacific</a> Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025

Regent Pacific Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin™/Senstend™, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application (NDA) with China's National Medical Products Administration (NMPA). The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regent Pacific Group Ltd. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553023543"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553023543\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553023543?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553023543","market":"nz","top_or_hot":-1,"title":"Regent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RPGLF\">Regent Pacific</a> Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/00575\">Regent Pacific</a> Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin™/Senstend™, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application (NDA) with China's National Medical Products Administration (NMPA). The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regent Pacific Group Ltd. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-22 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RPGLF\">Regent Pacific</a> Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/00575\">Regent Pacific</a> Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin™/Senstend™, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application (NDA) with China's National Medical Products Administration (NMPA). The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regent Pacific Group Ltd. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00575","symbol_name":"励晶太平洋","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL9GsK51:1","article_id":"2553023543","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553023543","pubTimestamp":1753174808,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Regent Pacific Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin/Senstend, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application  with China's National Medical Products Administration . The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00575":"励晶太平洋"},"translate_title":"Regent Pacific Group Ltd.宣布Senstend NDA审查取得进展™在中国，预计2025年底获得批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00575":0.9},"content_text":"Regent Pacific Group Ltd. Announces Progress in NDA Review for Senstend™ in China, Approval Expected by End of 2025\n    \n\nRegent Pacific Group Ltd. has announced a significant update regarding the ongoing regulatory review of its product, Fortacin™/Senstend™, in China. The company's commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., is actively progressing the new drug application (NDA) with China's National Medical Products Administration (NMPA). The review process has moved forward with Wanbang Biopharmaceutical submitting a comprehensive response to the first round of questions from the NMPA. Additionally, 900 commercial samples have been submitted to the Centre of Drug Evaluation. The company remains optimistic about obtaining NDA approval by the end of 2025, with commercial launch anticipated in the first quarter of 2026. Upon approval, Regent Pacific Group Ltd. is set to receive a payment of US$5 million from Wanbang Biopharmaceutical.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regent Pacific Group Ltd. published the original content used to generate this news brief on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}